Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Gamida Cell Ltd. is a biotechnology company focused on cell therapy for cancer and rare diseases, primarily leveraging its proprietary NAM technology to enhance the efficacy of stem cell transplants. The company operates in the U.S. and Israel, with key products in clinical trials, including its lead candidate, NiCord, which aims to improve outcomes for patients with hematological malignancies.
Gamida Cell generates revenue through partnerships with pharmaceutical companies for the development and commercialization of its cell therapy products. The company has a unique competitive advantage due to its proprietary NAM technology, which enhances the engraftment and proliferation of hematopoietic stem cells, potentially leading to better patient outcomes.
Clinical trial results for NiCord and other candidates
Regulatory approvals from the FDA and EMA
Partnership announcements with larger pharmaceutical companies
Market adoption rates of therapies post-approval
Regulatory changes that could impact approval processes for new therapies
Technological disruption from competing cell therapy innovations
Emerging competitors with similar cell therapy technologies
Established biotech firms with greater resources and market presence
High cash burn rate leading to potential liquidity issues
Dependence on external funding for R&D and operational costs
low - The demand for biotech therapies is less correlated with the economic cycle, as healthcare spending is often less sensitive to economic downturns.
Moderate - Rising interest rates can increase the cost of capital for funding clinical trials and operations, potentially impacting the company's financial flexibility.
minimal - The company has a negative debt/equity ratio, indicating reliance on equity financing rather than debt.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock is likely to experience significant price fluctuations based on clinical trial outcomes and regulatory news.
